The management of primary cutaneous melanoma in Victoria in 1996 and 2000.

The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Abstract Text:

John W Kelly,Michael A Henderson,Vicky J Thursfield,John Slavin,Jill Ainslie,Graham G Giles,John W Kelly,Michael A Henderson,Vicky J Thursfield,John Slavin,Jill Ainslie,Graham G Giles,

OBJECTIVE: To describe tumour characteristics and clinical management of melanomas newly diagnosed in 1996 and in 2000--before and after publication of the clinical practice "Guidelines for the management of cutaneous melanoma" by the Australian Cancer Network (1997), and their endorsement by the National Health and Medical Research Council (NHMRC) and republication (1999). DESIGN AND SETTING: Survey of clinicians involved in the management of patients with melanoma sampled from the Victorian Cancer Registry. The Registry is notified of all cases of cancer diagnosed by pathology laboratories and hospitals in both the public and private health sectors in the state of Victoria. PATIENTS: People with a cutaneous melanoma newly diagnosed in 1996 and 2000. All invasive melanomas > 1.50 mm in thickness were included, and for each year random samples were selected of 100 each of invasive melanomas 0.76-1.50 mm in thickness, invasive melanomas < or = 0.75 mm, and in-situ melanomas, plus 50 melanomas of unknown thickness. MAIN OUTCOME MEASURES: Biopsy method, adequacy of pathology reporting, adequacy of definitive excision (compared with margins recommended by the Guidelines), and follow-up procedures. RESULTS: The use of partial biopsies increased between 1996 and 2000. Recommended margins of definitive excision were used in only 33.6% of cases. Margins were smaller than recommended for 36% of in-situ melanomas, risking recurrence of primary melanoma. Documented follow-up examinations for subsequent primary skin malignancy were uncommon (6%). CONCLUSIONS: Many aspects of the management of primary cutaneous melanoma appear not to meet the recommendations of the published Guidelines. Further studies to explore the reasons for failure to meet the Guideline recommendations are needed.

The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Publishing Authors By Initials

JW Kelly,MA Henderson,VJ Thursfield,J Slavin,J Ainslie,GG Giles,JW Kelly,MA Henderson,VJ Thursfield,J Slavin,J Ainslie,GG Giles,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Medical journal of Australia

VOLUME: 187

Page Numbers: 511-4

Journal Abbreviation: Med. J. Aust.

ISSN: 0025-729X

DAY: 5

MONTH: Nov

YEAR: 2007

The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 400714

The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The management of primary cutaneous melanoma in Victoria in 1996 and 2000. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The management of primary cutaneous melanoma in Victoria in 1996 and 2000.

AFFILIATION: Victorian Melanoma Service and Dermatology Unit, Alfred Hospital, Melbourne, Victoria, Australia. kellyderm@bigpond.com

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Med J Aust

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The management of primary cutaneous melanoma in Victoria in 1996 and 2000 Related Publications

• A perspective on telmisartan and cardiovascular risk.
• Adverse childhood experiences and childhood autobiographical memory disturbance.
• Adverse childhood experiences and prescribed psychotropic medications in adults.
• Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.
• Assessing adaptive behaviour in the post-acute setting following traumatic brain injury: initial reliability and validity of the Adaptive Behaviour and Community Competency Scale (ABCCS).
• Bayesian inference for stochastic epidemic models with time-inhomogeneous removal rates.
• Blood pressure-the better biomarker: delay in clinical application.
• Brain stem gliomas: Patterns of Care in Victoria from 1998-2000.
• Cloretazine for the treatment of acute myeloid leukemia.
• Computational capabilities of recurrent NARX neural networks.
• Expression and regulation of anti-mullerian hormone in an oviparous species, the hen.
• Financial implications of plans to combat methicillin-resistant Staphylococcus aureus (MRSA) in an orthopaedic department.
• Hormone therapy and breast cancer: what factors modify the association?
• Institution of universal screening for Group B streptococcus (GBS) from a risk management protocol results in reduction of early-onset GBS disease in a tertiary obstetric unit.
• Is cancer risk associated with anger control and negative affect? Findings from a prospective cohort study.
• Learning long-term dependencies in NARX recurrent neural networks.
• Nelarabine activity in acute biphenotypic leukemia.
• Nicotine in blood in relation to smoking.
• Occupational exposure to ionizing and non-ionizing radiation and risk of glioma.
• On the distribution of performance from multiple neural-network trials.
• Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
• RECENT CASES OF DENTAL MALPRACTICE.
• Recurrent ectopic pregnancy.
• The cardiometabolic syndrome and calcium channel blocker combination drugs.
• The enduring effects of abuse and related adverse experiences in childhood : A convergence of evidence from neurobiology and epidemiology.
• The management of primary cutaneous melanoma in Victoria in 1996 and 2000.
• The oxygen effect on radiation-induced chromosome aberrations: breakage-versus-recombination hypotheses.
• The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.
• The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
• Treatment of acute lymphoblastic leukaemia : a new era.